Biochemical Study to Assess the Level of Galectin-1 in Type � Diabetic Patients with Renal Failure Undergoing Hemodialysis

Abstract

Rasha Hasan Jasim and Wedyan Mohammed Torki.

Backgrounds: Renal failure is a general problem worldwide as millions of patients are diagnosed each year and many deaths are caused by this disease. Renal failure is the fourth cause of death in the world, in general, it means a deterioration in the ability of the kidneys to perform their functions or a decrease in the glomerular filtration rate. Therefore, wastes accumulate, and symptoms of renal failure appear and are either acute or chronic. The prevalence of kidney failure is estimated at about 16% worldwide and it is believed that the number of injuries reaches 69.9 million in 2025 unless urgent preventive measures are taken. Renal failure is one of the complications of diabetes, as in 50% of people with diabetes it is considered a chronic disease characterized by high glucose sugar in the blood as a result of decrease of insulin secretion or poor mechanical representation or both.
Subjects: The current study included 88 people who were divided into two groups: the first included 50 patients suffering from kidney failure (18 females and 32 males), their ages range between (36-78 years) and they are subject to dialysis, while the second group included 38 individuals (11 females and 27 males) their ages range between (31-64 years), as a control group. Aim of study: The current study is designed to find out the levels of Galactin-1 in the sera of study individuals.
Results: The present study shows a significant increase (p<0.05) in the levels of Galactin-1 in the diabetic kidney group compared with the healthy group.
Conclusions: Kidney complications of type Π diabetes can develop in the patients regardless their gender or age. Galectin-1 is an excellent diagnostic tool for diagnosing kidney failure caused by the complications of diabetes and for predicting the kidney's efficiency to perform its vital functions.